US2013252347A1PendingUtilityA1

Diagnostic method

Assignee: HANSA MEDICAL ABPriority: Jun 12, 2007Filed: Mar 12, 2013Published: Sep 26, 2013
Est. expiryJun 12, 2027(~0.9 yrs left)· nominal 20-yr term from priority
G01N 33/6893G01N 2800/26G01N 33/569A61P 31/04A61B 5/00A61K 39/00G01N 33/575
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . An agent for the detection of HBP for use in determining whether or not an individual is at risk of developing severe sepsis. 
     
     
         17 . An agent according to  claim 16  wherein the agent comprises an HBP-specific antibody. 
     
     
         18 - 21 . (canceled) 
     
     
         22 . A test kit for use in a method for determining whether or not an individual is at risk of developing severe sepsis, which test kit comprises an agent for the detection of HBP in an individual. 
     
     
         23 . The kit of claim  21  additionally comprising means for the measurement of the WBC in an individual.

Join the waitlist — get patent alerts

Track US2013252347A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.